Demand for alternative drug delivery methods has the potential to reshape therapeutic markets and improve clinical outcomes. New innovations, especially oral alternatives, are poised to drive broad changes across the entire sector.
Surge Therapeutics' hydrogel is engineered to deliver a cancer immunotherapy. Rather than replace surgery, CEO Michael Goldberg says the hydrogel could supplement this standard of care for solid tumors. The startup's Series A financing will support the technology's first test in humans.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Vector BioPharma has launched from the biotech startup incubator of Versant Ventures, which is backing the company with a $30 million Series A financing. Vector is developing virus-like particles with the capability to deliver large payloads of genetic medicines to a wide range of tissues.
By adding adherence and connectivity capabilities to home-based solutions, clinicians can maintain open lines of communication with patients, helping patients better care for themselves from the comfort of their homes.
In less than one year, ReCode Therapeutics has reeled in $200 million in financing. Big pharmaceutical companies are taking notice of the biotech startup’s technology, which enables lipid nanoparticles to go a wide range of organs and tissues, potentially broadening the reach of genetic medicines.
Regulatory setbacks for a new migraine treatment have led Zosano Pharma to restructure, laying off about 31% of its staff. Zosano is one of several biotechs that announced cost-saving measures this week.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The time is ripe for wide adoption of wearable drug delivery devices as more patients seek home care in a lower-cost setting and because these devices are able to deliver complex, highly viscose drugs currently being developed.
Company raises $5 million from Lagunita Biosciences for technology to improve eye drug administration.
Drug delivery may not mean swallowing a pill or getting a shot anymore. From dissolvable wafers to micro-robots, drug delivery is changing for the better.
MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences Purdue University spinout Biokorf is developing a new way to manufacture pharmaceuticals, attempting to personalize drug dosage and delivery methods. It’s certainly an interesting endeavor in this era of precision medicine. Chief Scientific Officer Rodolfo Pinal put the use-case […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.